Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have spe…
Biotechnology
US, Boston [HQ]
Cash Flow Statements
15 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||
| Operating Cash Flow (OCF) | -427.00 | -635.00 | 143.00 | 267.00 | -51.00 | -513.00 | -365.00 | 236.00 | 844.00 | 1,270.00 | 1,569.00 | 3,253.00 | 2,643.00 | 4,129.00 | 3,537.00 | |
| Operating Cash (Net) | -427.00 | -635.00 | 143.00 | 267.00 | -51.00 | -513.00 | -365.00 | 236.00 | 844.00 | 1,270.00 | 1,569.00 | 3,253.00 | 2,643.00 | 4,129.00 | 3,537.00 | |
| Accounts Receivable | 13.00 | -2.00 | -170.00 | 39.00 | 53.00 | 7.00 | -104.00 | -33.00 | -71.00 | -108.00 | -225.00 | -223.00 | -274.00 | -358.00 | -84.00 | |
| Accounts Payable | -15.00 | -1.00 | 37.00 | 14.00 | -49.00 | 25.00 | -1.00 | -11.00 | 8.00 | 36.00 | -22.00 | 51.00 | 31.00 | 120.00 | 48.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Change | 61.00 | -63.00 | -193.00 | -13.00 | -5.00 | -11.00 | -85.00 | -2.00 | 15.00 | 238.00 | -66.00 | -54.00 | -105.00 | 340.00 | -265.00 | |
| Other WC | 53.00 | -65.00 | 51.00 | -38.00 | -16.00 | -27.00 | 43.00 | 59.00 | 123.00 | 341.00 | 246.00 | 249.00 | 230.00 | 715.00 | 92.00 | |
| Investing Activities | ||||||||||||||||
| Used Cash (Net) | -508.00 | 7.00 | 212.00 | -425.00 | -54.00 | 73.00 | 268.00 | 104.00 | -437.00 | -202.00 | -1,235.00 | 99.00 | -340.00 | -321.00 | -3,141.00 | |
| Capital Expenditure | -23.00 | -38.00 | -94.00 | -71.00 | -51.00 | -51.00 | -45.00 | -56.00 | -259.00 | -95.00 | -75.00 | -259.00 | -235.00 | -204.00 | -258.00 | |
| Purchases of Investments | -1,186.00 | -1,234.00 | -721.00 | -1,705.00 | -2,412.00 | -1,424.00 | -633.00 | -629.00 | -532.00 | -515.00 | -576.00 | -450.00 | -605.00 | -740.00 | -3,817.00 | |
| Sale/Maturity of Investment | 788.00 | 1,284.00 | 1,016.00 | 1,367.00 | 2,348.00 | 1,557.00 | 1,067.00 | 757.00 | 369.00 | 431.00 | 570.00 | 809.00 | 499.00 | 920.00 | 934.00 | |
| Property, Plant, Equipment (P&PE) | -23.00 | -38.00 | -94.00 | -71.00 | -51.00 | -51.00 | -45.00 | -56.00 | -259.00 | -95.00 | -75.00 | -259.00 | -235.00 | -204.00 | -258.00 | |
| Acquisitions (Net) | -87.00 | - - | -60.00 | - - | - - | -10.00 | -80.00 | - - | -160.00 | - - | -1,154.00 | -418.00 | 76.00 | -295.00 | -6.00 | |
| Other Investing Activities | - - | -4.00 | 72.00 | -16.00 | 61.00 | 1.00 | -40.00 | 33.00 | 145.00 | -22.00 | -5.00 | 418.00 | -76.00 | 179.00 | 6.00 | |
| Financing Activities | ||||||||||||||||
| Used Cash (Net) | -999.00 | -425.00 | -124.00 | -172.00 | -180.00 | -497.00 | -188.00 | -133.00 | -68.00 | -71.00 | -126.00 | -505.00 | -1,478.00 | -67.00 | -562.00 | |
| Debt Repayment | - - | - - | -250.00 | -21.00 | -83.00 | -81.00 | -20.00 | -93.00 | -319.00 | -33.00 | -39.00 | -42.00 | -47.00 | -85.00 | -44.00 | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
558 | - - | - - | - - | - - | - - | - - | - - | - - | 639 | 535 | 1,004 | 1,663 | 358 | 562 | |
| Issued | 849.00 | 33.00 | 124.00 | 191.00 | 265.00 | 274.00 | 185.00 | 68.00 | 344.00 | 289.00 | 343.00 | 264.00 | 102.00 | 186.00 | 134.00 | |
| Repurchased | 290.00 | - - | - - | - - | - - | - - | - - | - - | - - | -350.00 | -192.00 | -739.00 | -1,561.00 | -172.00 | -427.00 | |
| Other Financing Activities | 149.00 | 391.00 | - - | 1.00 | -1.00 | 304.00 | 23.00 | 158.00 | 42.00 | 43.00 | 24.00 | 276.00 | 130.00 | 3.00 | -224.00 | |
| Cash Balances | ||||||||||||||||
| Begin of Period | 389.00 | 446.00 | 243.00 | 475.00 | 489.00 | 569.00 | 625.00 | 714.00 | 1,183.00 | 1,667.00 | 2,658.00 | 3,120.00 | 5,988.00 | 6,800.00 | 10,512.00 | |
| End of Period | 446.00 | 243.00 | 475.00 | 489.00 | 569.00 | 625.00 | 714.00 | 1,183.00 | 1,665.00 | 2,658.00 | 3,120.00 | 5,988.00 | 6,800.00 | 10,512.00 | 10,372.00 | |
| Change | 57.00 | -203.00 | 232.00 | 14.00 | 79.00 | 55.00 | 89.00 | 469.00 | 481.00 | 990.00 | 462.00 | 2,868.00 | 811.00 | 3,711.00 | -139.00 | |
| Non-Cash Balances | ||||||||||||||||
| Depreciation and Amortization | 30.00 | 30.00 | 35.00 | 38.00 | 48.00 | 63.00 | 62.00 | 61.00 | 61.00 | 72.00 | 106.00 | 109.00 | 125.00 | 148.00 | 181.00 | |
| Stock Based Compensation | 86.00 | 97.00 | 126.00 | 114.00 | 127.00 | 177.00 | 231.00 | 237.00 | 290.00 | - - | 360.00 | 429.00 | 441.00 | 491.00 | 581.00 | |
| Other | 38.00 | - - | 141.00 | 143.00 | 750.00 | - - | 12.00 | 6.00 | 506.00 | 60.00 | -176.00 | -220.00 | -5.00 | 103.00 | -42.00 | |
| Highlighted metrics | ||||||||||||||||
| Free Cash Flow (FCF) | -451.00 | -673.00 | 49.00 | 196.00 | -102.00 | -564.00 | -410.00 | 179.00 | 585.00 | 1,174.00 | 1,493.00 | 2,993.00 | 2,408.00 | 3,925.00 | 3,278.00 | |
| Cash Conversion Cycle (CCC) | -916.00 | -996.00 | 218.00 | -58.00 | -72.00 | -195.00 | 7.00 | 71.00 | 91.00 | 60.00 | 108.00 | 114.00 | 118.00 | 111.00 | 166.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||||||||||||
| Forex Effect on Cash | -5.00 | - - | - - | - - | 4.00 | -2.00 | -2.00 | -4.00 | 5.00 | -6.00 | 1.00 | 20.00 | -13.00 | -29.00 | 26.00 |